Maxigen Biotech Inc (1783) — Capital Reinvestment Ratio
Maxigen Biotech Inc (1783) has a Capital Reinvestment Ratio of 0.23x as of June 2026, meaning it reinvests 0% of its operating cash flow (NT$74.75 Million) in capital expenditures (NT$17.01 Million). Check how tangible is Maxigen Biotech Inc's equity to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Maxigen Biotech Inc Capital Reinvestment Ratio (2009–2025)
This chart tracks Maxigen Biotech Inc's Capital Reinvestment Ratio across 12 annual periods. For the full cash flow conversion analysis, see 1783 operating cash flow.
Annual Capital Reinvestment Ratio for Maxigen Biotech Inc (2009–2025)
Year-by-year Capital Reinvestment Ratio for Maxigen Biotech Inc from 2009 to 2025. See Maxigen Biotech Inc (1783) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.28x | NT$290.22 Million | NT$82.63 Million | ▲ +167.3% |
| 2024 | 0.11x | NT$298.22 Million | NT$31.77 Million | ▼ -18.7% |
| 2023 | 0.13x | NT$171.20 Million | NT$22.44 Million | ▲ +143.6% |
| 2022 | 0.05x | NT$268.34 Million | NT$14.44 Million | ▼ -59.0% |
| 2021 | 0.13x | NT$117.59 Million | NT$15.45 Million | ▼ -13.8% |
| 2020 | 0.15x | NT$74.39 Million | NT$11.34 Million | ▼ -39.4% |
| 2019 | 0.25x | NT$94.42 Million | NT$23.74 Million | ▲ +112.0% |
| 2018 | 0.12x | NT$170.58 Million | NT$20.23 Million | ▼ -83.2% |
| 2017 | 0.70x | NT$41.18 Million | NT$29.01 Million | ▼ -66.4% |
| 2016 | 2.09x | NT$34.72 Million | NT$72.71 Million | ▲ +487.8% |
| 2012 | 0.36x | NT$17.53 Million | NT$6.24 Million | ▼ -9.9% |
| 2009 | 0.40x | NT$19.27 Million | NT$7.62 Million | — |